Half: A prospective Multi-Centre phase II clinical trial
evaluating the efficacy and safety of tyrosine kinase
inhibitors' discontinuation after two-step dose reduction in
patients with chronic myeloid leukemia in deep molecular
remission.

a 2021

Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.

ŽÁČKOVÁ, Daniela, Edgar FABER, L. STEJSKAL, M. KARAS, Petra BĚLOHLÁVKOVÁ et. al.

Basic information

Original name

Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.

Authors

ŽÁČKOVÁ, Daniela (203 Czech Republic, guarantor, belonging to the institution), Edgar FABER (703 Slovakia), L. STEJSKAL, M. KARAS, Petra BĚLOHLÁVKOVÁ (203 Czech Republic), H. KLAMOVÁ, O. ČERNÁ, Eduard CMUNT (203 Czech Republic), Petra ČIČÁTKOVÁ (203 Czech Republic, belonging to the institution), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), Tomáš HORŇÁK (703 Slovakia, belonging to the institution), Anežka KVETKOVÁ (703 Slovakia, belonging to the institution), Jiřina PROCHÁZKOVÁ (203 Czech Republic, belonging to the institution), Jitka RYCHLÍČKOVÁ (203 Czech Republic, belonging to the institution), Radka ŠTĚPÁNOVÁ (203 Czech Republic, belonging to the institution), Adam SVOBODNÍK (203 Czech Republic, belonging to the institution), Kateřina MACHOVÁ POLÁKOVÁ (203 Czech Republic), Ivana JEŽÍŠKOVÁ (203 Czech Republic, belonging to the institution), Tomáš JURČEK (203 Czech Republic, belonging to the institution), Marek BORSKÝ (203 Czech Republic, belonging to the institution), Ondřej WIEWIORKA (203 Czech Republic), Regina DEMLOVÁ (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

63rd ASH Annual Meeting and Exposition in Blood, 2021

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 25.476

RIV identification code

RIV/00216224:14110/21:00125334

Organization unit

Faculty of Medicine

ISSN

DOI

http://dx.doi.org/10.1182/blood-2021-146221

UT WoS

000736413906171

Keywords in English

Tyrosine Kinase Inhibitors' Discontinuation; Two-Step Dose Reduction; Chronic Myeloid Leukemia

Abstract

V originále

Treatment-free remission (TFR) has become a new treatment goal for chronic myeloid leukemia (CML) patients. However, usually abrupt tyrosine kinase inhibitors (TKIs) therapy discontinuation has been successful only in about half of eligible patients and it can cause burdening TKI withdrawal syndrome (TWS) in about 30% of them. Moreover, any robust clinical or biological factor predictive for successful TFR has not been identified yet. On top of that, sustainable deep molecular response (DMR) as the main prerequisite for TKI discontinuation attempt is achieved only in 20-40% of patients. The majority of CML patients, therefore, need to be treated with the effective and well-tolerated drug for a long time or even life-long.

Links

MUNI/A/1595/2020, interní kód MU

Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VIII (Acronym: VýDiTeHeMa VIII)

Investor: Masaryk University

90128, large research infrastructures

Name: CZECRIN III

Citovat

ŽÁČKOVÁ, Daniela, Edgar FABER, L. STEJSKAL, M. KARAS, Petra BĚLOHLÁVKOVÁ, H. KLAMOVÁ, O. ČERNÁ, Eduard CMUNT, Petra ČIČÁTKOVÁ, Lukáš SEMERÁD, Tomáš HORŇÁK, Anežka KVETKOVÁ, Jiřina PROCHÁZKOVÁ, Jitka RYCHLÍČKOVÁ, Radka ŠTĚPÁNOVÁ, Adam SVOBODNÍK, Kateřina MACHOVÁ POLÁKOVÁ, Ivana JEŽÍŠKOVÁ, Tomáš JURČEK, Marek BORSKÝ, Ondřej WIEWIORKA, Regina DEMLOVÁ and Jiří MAYER. Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission. In 63rd ASH Annual Meeting and Exposition in Blood. 2021. ISSN 0006-4971. Available from: https://dx.doi.org/10.1182/blood-2021-146221.

@proceedings{1830798,
   author = {Žáčková, Daniela and Faber, Edgar and Stejskal, L. and Karas, M. and Bělohlávková, Petra and Klamová, H. and Černá, O. and Cmunt, Eduard and Čičátková, Petra and Semerád, Lukáš and Horňák, Tomáš and Kvetková, Anežka and Procházková, Jiřina and Rychlíčková, Jitka and Štěpánová, Radka and Svobodník, Adam and Machová Poláková, Kateřina and Ježíšková, Ivana and Jurček, Tomáš and Borský, Marek and Wiewiorka, Ondřej and Demlová, Regina and Mayer, Jiří},
   booktitle = {63rd ASH Annual Meeting and Exposition in Blood},
   doi = {http://dx.doi.org/10.1182/blood-2021-146221},
   keywords = {Tyrosine Kinase Inhibitors' Discontinuation; Two-Step Dose Reduction; Chronic Myeloid Leukemia},
   language = {eng},
   title = {Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.},
   url = {https://ashpublications.org/blood/article/138/Supplement%201/3606/479768/Half-A-Prospective-Multi-Centre-Phase-II-Clinical},
   year = {2021}
}

TY  - CONF
ID  - 1830798
AU  - Žáčková, Daniela - Faber, Edgar - Stejskal, L. - Karas, M. - Bělohlávková, Petra - Klamová, H. - Černá, O. - Cmunt, Eduard - Čičátková, Petra - Semerád, Lukáš - Horňák, Tomáš - Kvetková, Anežka - Procházková, Jiřina - Rychlíčková, Jitka - Štěpánová, Radka - Svobodník, Adam - Machová Poláková, Kateřina - Ježíšková, Ivana - Jurček, Tomáš - Borský, Marek - Wiewiorka, Ondřej - Demlová, Regina - Mayer, Jiří
PY  - 2021
TI  - Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.
KW  - Tyrosine Kinase Inhibitors' Discontinuation
KW  - Two-Step Dose Reduction
KW  - Chronic Myeloid Leukemia
UR  - https://ashpublications.org/blood/article/138/Supplement%201/3606/479768/Half-A-Prospective-Multi-Centre-Phase-II-Clinical
N2  - Treatment-free remission (TFR) has become a new treatment goal for chronic myeloid leukemia (CML) patients. However, usually abrupt tyrosine kinase inhibitors (TKIs) therapy discontinuation has been successful only in about half of eligible patients and it can cause burdening TKI withdrawal syndrome (TWS) in about 30% of them. Moreover, any robust clinical or biological factor predictive for successful TFR has not been identified yet. On top of that, sustainable deep molecular response (DMR) as the main prerequisite for TKI discontinuation attempt is achieved only in 20-40% of patients. The majority of CML patients, therefore, need to be treated with the effective and well-tolerated drug for a long time or even life-long.
ER  -

ŽÁČKOVÁ, Daniela, Edgar FABER, L. STEJSKAL, M. KARAS, Petra BĚLOHLÁVKOVÁ, H. KLAMOVÁ, O. ČERNÁ, Eduard CMUNT, Petra ČIČÁTKOVÁ, Lukáš SEMERÁD, Tomáš HORŇÁK, Anežka KVETKOVÁ, Jiřina PROCHÁZKOVÁ, Jitka RYCHLÍČKOVÁ, Radka ŠTĚPÁNOVÁ, Adam SVOBODNÍK, Kateřina MACHOVÁ POLÁKOVÁ, Ivana JEŽÍŠKOVÁ, Tomáš JURČEK, Marek BORSKÝ, Ondřej WIEWIORKA, Regina DEMLOVÁ and Jiří MAYER. Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission. In \textit{63rd ASH Annual Meeting and Exposition in Blood}. 2021. ISSN~0006-4971. Available from: https://dx.doi.org/10.1182/blood-2021-146221.

Detailed Information on Publication Record